PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30739218-9	2019	RESULTS: Ropivacaine pre-treatment significantly reduced AR scores (median 3 [minimum-maximum 2-4] for control vs. 2 [1-2] for ropivacaine, p < 0.001) and plasma levels of tumor necrosis factor-alpha (p = 0.01) compared to control, whereas plasma concentrations of interleukin - 6 (p = 0.008) and - 10 (p < 0.001) were increased by ropivacaine.	Ropivacaine	9-20	tumor necrosis factor	Mus musculus	172-199	
10748280-0	2000	Inhibitory actions of ropivacaine on tumor necrosis factor-alpha-induced leukocyte adhesion and tissue accumulation in vivo.	Ropivacaine	22-33	tumor necrosis factor	Mus musculus	37-64	
10748280-1	2000	We have examined the effect of ropivacaine, a local anesthetic, on leukocyte-endothelium interactions induced by tumor necrosis factor-alpha (TNF-alpha) in vivo by the use of intravital microscopy in the mouse cremaster microcirculation.	Ropivacaine	31-42	tumor necrosis factor	Mus musculus	113-140	
10748280-1	2000	We have examined the effect of ropivacaine, a local anesthetic, on leukocyte-endothelium interactions induced by tumor necrosis factor-alpha (TNF-alpha) in vivo by the use of intravital microscopy in the mouse cremaster microcirculation.	Ropivacaine	31-42	tumor necrosis factor	Mus musculus	142-151	
10748280-2	2000	It was found that ropivacaine markedly reduced venular leukocyte adhesion and tissue recruitment in response to TNF-alpha challenge, whereas leukocyte rolling was unchanged.	Ropivacaine	18-29	tumor necrosis factor	Mus musculus	112-121